Results 231 to 240 of about 35,140 (296)
Cancer Medicine, Volume 15, Issue 3, March 2026.RETRACTION: L. Wang, K. Li, C. Wang, X. Shi, and H. Yang, “miR‐107 Regulates Growth and Metastasis of Gastric Cancer Cells via Activation of the PI3K‐AKT Signaling Pathway by Down‐Regulating FAT4,” Cancer Medicine 8, no. 11 (2019): 5264–5273, https://doi.org/10.1002/cam4.2396. The above article, published online on 12 July 2019 in Wiley Online Library (
wiley +1 more source
Cancer Medicine, Volume 15, Issue 3, March 2026.ABSTRACT Background Esophageal squamous cell cancer (ESCC) is a malignancy derived from the Esophagus, and dysregulation of the cGAS‐STING pathway contributes to ESCC progression. Method ESCC bulk‐seq dataset GSE38129 was acquired from GEO database and then underwent Limma and WGCNA analysis for the identification of shared DEGs, which were intersected
Chunyang Zhou +3 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 3, March 2026.ABSTRACT Background A comprehensive preoperative assessment of the patient's physical condition is crucial for predicting the prognosis of patients undergoing radical cholecystectomy for gallbladder cancer (GBC). This study aimed to develop a prognostic model integrating preoperative hematological parameters and clinical information to predict ...
Mingyang Wang +4 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 3, March 2026.ABSTRACT Introduction The European Summary of Product Characteristics (SmPC) for 5‐FU warns of significant granulocyte decline when combined with thiazides, cyclophosphamide, or methotrexate, based on a 1981 cohort of 14 patients. Despite limited evidence, drug‐interaction checkers still flag this risk.
Gerard Ronda‐Roca +5 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 3, March 2026.ABSTRACT Background Imeglimin (IME) is a novel oral anti‐diabetic agent with a similar chemical structure to metformin, which has shown broad‐spectrum anti‐tumor activity. However, the activity of imeglimin on tumor cells remains unclear. This study investigated the effects of IME on multiple myeloma (MM) cells and explored the underlying mechanisms ...
Jifeng Jiang +6 more
wiley +1 more source
Symptom Clusters and Symptom Burden in Cancer Survivors
Cancer Medicine, Volume 15, Issue 3, March 2026.ABSTRACT Context Limited information is available on the symptom burden and symptom clusters in cancer survivors. Objectives Describe the occurrence, severity, and distress of 44 symptoms; determine risk factors associated with a higher symptom burden; and evaluate for symptom clusters using symptom occurrence rates.
Marilyn J. Hammer +12 more
wiley +1 more source
Native American Women's Willingness to Screen for Both Cervical and Colorectal Cancer at Home
Cancer Medicine, Volume 15, Issue 3, March 2026.ABSTRACT Introduction Fewer than 50% of Native American (NA) women screen for both cervical and colorectal (CRC) cancer. We aim to explore the perspectives of NAs around cervical and colorectal cancer home‐based self‐screening options. Methods The NA community provided review and approval for this cross‐sectional survey on cancers in general, and ...
Keely K. Ulmer +6 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 3, March 2026.ABSTRACT Background Unpaid caregiving is a critical but often under‐recognised component of the cancer care continuum. As cancer prevalence rises globally, particularly in lower‐income countries, quantifying the time and economic burden of unpaid caregiving across regions is essential for health resource planning, economic participation and support ...
Lan Gao +6 more
wiley +1 more source